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Colorectal cancer continues to be a challenging clinical problem. It is one of the
most common cancers and ranks fourth in frequency in men and third in women
worldwide.1 About 70% of all patients diagnosed with colorectal cancer undergo
potentially curative surgery, however, half of those present with or develop
advanced local disease or metastases. Advanced colorectal cancer has a poor
prognosis with a median survival of only a few months range, (6-15 months),
despite aggressive chemotherapy and/or surgical resection.2 The heterogeneity of
tumor response to chemotherapy is a significant obstacle in cancer treatment,
including colorectal cancer. This means that tumors with similar histopathological
characteristics may have different clinical outcomes and responsiveness to therapy.3
This explains how the appropriate choice of drug is mandatory for better
prognosis and why chemosensitivity testing has been of great interest to
oncologists in recent years.
In an attempt to individualize therapy, a number of in vitro chemosensitivity
assays have been developed to predict therapeutic response and correlated the test
results with clinical response. A review of 12 published in vitro assays by
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study explored the feasibility of ATP-CRA as a chemosensitivity test in patients with colorectal cancer. Materials
and Methods: A total of 118 patients who underwent surgical resection for colorectal adenocarcinoma were
analyzed for chemosensitivity to 6 anticancer drugs using ATP-CRA. We calculated the cell death rate (CDR) by
measuring intracellular ATP levels of drug-exposed cells and untreated controls. Results: Interpretable results were
available for 85.5% (118/138) of patients. The mean coefficient of variation for triplicate ATP measurements was
9.2%. The highest CDR was observed in irinotecan (34.0%) and the lowest CDR in etoposide (21.0%). Paclitaxel
had the broadest range of CDR (0-86.7%) and 5-FU had the narrowest range of CDR (0-56.8%). The overall
highest responsiveness was seen most prevalently in irinotecan (24.7%, 23/93 patients). Irinotecan had the greatest
responsiveness in patients with well differentiated and moderately differentiated carcinoma. Conclusion: Our study
suggests that ATP-CRA could be used to identify patients with colorectal cancer who might benefit from treatment
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INTRODUCTION
Cortazar and Johnson.4 showed that the mean response rate
for patients treated with in vitro-selected therapy was 27%
compared to 18% in patients treated with empiric therapy.
Although in vitro-selected chemotherapy seems to be at
least as good as empiric regimens, this therapy in actuality
is not widely used in clinical practice because the potential
clinical benefit has not been adequately addressed and
various technical problems have been encountered with
this assay.5-9
The adenosine triphosphate-based assay (ATP assay) is
a sensitive assay that evaluates tumor cell viability by
measuring intracellular ATP levels of drug-exposed cells
and an untreated control. Furthermore, this assay has been
somewhat widely studied because its clinical feasibility
was validated in the field of various cancers, including
melanoma, breast cancer, stomach cancer, and ovarian
cancer.10-15 ATP-CRA is a new method which improved
previous ATP assays, thus making it possible to inhibit the
proliferation of normal cells in tumor tissue using the ultra-
low attachment culture plates, does not require a large
amount of specimens, and has a relatively short test turn-
around time.16 However, a few studies have applied the
ATP assay to patients with colorectal cancer to investigate
its clinical utility as a chemosensitivity assay.17-19
Therefore, we performed this preliminary study to explore
the feasibility and clinical usefulness of ATP-CRA as a
chemosensitivity assay in patients with colorectal cancer,
focusing on the success rate, mean coefficient of variation,
and turnaround time.
Between June 2004 and October 2005, we enrolled a total
of 138 consecutive patients who underwent surgical
resection for colorectal cancer at Gangnam Severance
Hospital and the Yonsei University Health System. Eligible
patients had histologically confirmed primary adenocar-
cinoma of the colon and rectum. Patients who had under-
gone preoperative chemoradiation therapy were excluded
from this study. This study was approved by the appropriate
Institutional Review Board and informed consent for
participation was never denied to any of patients.
ATP-CRA was performed as previously described.16
Tumor tissue specimens were taken at least 0.5 cm3 in size
in the operating room and delivered to the laboratory and
stored in Hank balanced salt solution (HBSS, Gibco,
Rockville, MD, USA) containing 100 IU/mL penicillin
(Sigma, St. Louis, MO, USA), 100 µg/mL streptomycin
(Sigma), 100 µg/mL gentamicin (Gibco), 2.5 µg/mL
amphotericin B (Gibco), and 5% fetal bovine serum (FBS,
Gibco). These tissue specimens were washed with ethanol,
quantified, and minced before being incubated at 37˚C for
12 to 16 hours with extracellular matrix-degrading enzymes,
such as dispase (Sigma) pronase (Sigma), and DNase
(Sigma). Cells were harvested using a cell strainer (BD
Falcon, Bedford, MA, USA). To eliminate normal cells, cell
suspensions were subjected to Ficoll gradient (Histopaque-
1077, 1.077 g/mL, Sigma) centrifugation at 400 g for 15
minutes. The viability of isolated cells was tested using
trypan blue exclusion.
Separated tumor cells were diluted to 2,000-20,000
viable cells/100 µL using Iscove modified Dulbecco medium
(IMDM, Gibco), including 10% FBS, and the cells were
then seeded in triplicate onto a 96-well, ultra-low attach-
ment microplate (Costar, Cambridge, MA, USA). These
microplates were able to restrict the growth of normal cells
such as fibroblasts. In the treated groups, 100 µL of
chemotherapeutic agents were added onto the seeded cells
and the cells were cultured for 48 hrs at 37˚C in a 5% CO2
incubator. In the untreated control groups, 100 µL of
IMDM, without chemotherapeutic agents, was added to 3-
6 wells of the microplates. For quality control, a negative
control group of 3-6 wells (seeding medium without cells)
and 2 positive control groups were included in the culture
plate. Each positive control group was composed of 3
wells that contained the minimal (105 pg ATP) and
median (280 pg ATP) amounts of ATP as measured in
1,000 tumor cells harvested from tissue. Three test drug
concentrations (TDC) were used in triplicate, including 20,
100, and 500% of the plasma peak concentrations
determined by training set experiments,20,21 which exhibited
a scattered distribution of cell deaths from each specimen
(data not shown). Standard 100% TDC values were
etoposide (3.6 µg/mL), 5-FU (10.0 µg/mL), gemcitabine
(16.9 µg/mL), irinotecan (4.7 µg/mL), oxaliplatin (2.9
µg/mL), and paclitaxel (8.5 µg/mL), which are chemo-
therapeutic agents studied in several preclinical and
research reports,17,22,23 and are also clinically active in
colorectal cancer. The successful evaluation at each con-
centration requires a minimum of 20 mg of tumor tissues.
Cells from the untreated control and treated groups were
lysed and the amount of ATP in the cell lysates was meas-
ured using luciferin and excessive luciferase (Roche,
Mannheim, Germany) followed by flash type lumine-
scence measurements on a Victor 3 multi-label counter
(PerkinElmer, Boston, MA, USA). Cell death rate (CDR)
was calculated as follows:
CDR (%) = (1-)×100
Mean luminescence in treated
Mean luminescence in untreeated 
A chemosensitivity index (CSI) was calculated by adding
the percentage of CDR at each concentration tested as
previously published.15
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CSI = 300 - sum (% CDR at 500, 100, and 20% TDC)
To calculate the intra-assay mean coefficient of variation
(CV) value, the luminescence values of each specimen
were measured 3 times. We then confirmed whether the
measured values at 280 pg of ATP were higher than those
at 105. If there were contamination of microorganism,
inadequate number of cells and an intra-assay mean CV
greater than 30, the test was considered a failure. If the
measured values in the untreated control were lower than
those in the positive group (105 pg of ATP), the specimen
was considered to have an unacceptable viability.
Statistical evaluation was carried out using the statistical
package SPSS for Windows (Version 11.0; SPSS Inc.,
Chicago, IL, USA). In vitro drug responsiveness was
correlated with tumor histology utilizing the repeated
measures analysis of variance. A value of p < 0.05 was
considered statistically significant.
Details of the patients’ characteristics are presented in
Table 1. The results of ATP-CRA in all cases were reported
within 7 days after obtaining the tumor tissues. Interpre-
table results were abtained in 85.5% (118/138) of the
specimens. The intra-assay mean coefficient of variation
(CV) for triplicate ATP measurements was 9.2%. The
failures were due to microbial contamination (18 cases)
and an insufficient amount of viable cells (2 cases).
According to the criteria of CDR, 19 (16.1%) assays of the
118 patient samples tested did not produce completely
evaluable results from all of the 6 drugs used, and 36
(30.5%) assays did not produce by CSI. This was due to
insufficient tissues and excessive CV values. Of the 6
drugs tested, the interpretable mean number of drugs at
TDC using 1 tumor tissue was 5.75 (95.8%). Moreover,
interpretable results of 3 clinically active drugs (5-FU,
oxaliplatin, and irinotecan) were available simultaneously
for 94.1% of the total samples (111/118). The difference in
interpretable case numbers for all drugs tested between
CDR and CSI is shown in Tables 2 and 3, respectively.
The cytotoxic effects for TDC of the chemotherapeutic
agents on cell death ranged from 0 to 86.7% (Table 2).
Irinotecan showed the highest median value of CDR
(34.0%), while paclitaxel had the widest range of
cytotoxic effects range, (0-86.7%). Etoposide achieved
the lowest median value of CDR (21.0%) and 5-FU had
the narrow-est range of cytotoxic effects range, (0-
56.8%).
Table 3 demonstrated the marked heterogeneity of CSI
to anticancer drugs between the tumors tested. The overall
highest responsiveness was observed most prevalently in
irinotecan (24.7%, 23/93). In addition, we calculated the
mean value of CSI according to the histological type of
colorectal cancers (Fig. 1). Irinotecan revealed the greatest
RESULTS
Table 1. Aatient Characteristics (n = 118)
Characteristics No. of patients (%)
Gender
Male 76 (64.4)
Female 42 (35.6)
Age
Mean 60.1
Range 26 - 83
Primary site
Ascending Colon 25 (21.2)
Transverse Colon 9 (7.7)
Descending Colon 3 (2.5)
Sigmoid Colon 25 (21.2)
Rectum 56 (47.4)
TNM
Stage I 19 (16.1)
Stage II 49 (41.5)
Stage III 33 (28.0)
Stage IV 17 (14.4)
Histology
Well differentiated 15 (12.7)
Moderately differentiated 82 (69.5)
Poorly differentiated 2 (1.7)
Mucinous 16 (13.6)
Other 3 (2.5)
Table 2. Cell Death Rate at 1X TDC*
5F OX IR ET GE PA
Tested no. 111 115 117 109 116 111
Mean ± SD (%)� 28.8 ± 13.1 26.3 ± 16.2 33.6 ± 18.0 26.0 ± 20.0 21.6 ± 15.6 27.8 ± 20.1
Median (%)� 31.0 28.5 34.0 21.0 22.0 25.2
Range (%)� 0 - 56.8 0 - 59.1 0 - 85.1 0 - 79.9 0 - 64.5 0 - 86.7
5F, 5-FU; OX, oxaliplatin; IR, irinotecan; ET, etoposide; GE, gemcitabine; PA, paclitaxel.
*TDC; is defined as the drug concentration at which tumors show the most heterogeneous inhibition rate.
�Unit is cell death rate.
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responsiveness in patients with well and moderately
differentiated carcinoma; whereas paclitaxel achieved the
greatest responsiveness in those with poorly differentiated
and mucinous carcinoma. However, we found no statisti-
cally significant association between the responsiveness
and histology (p = 0.144).
In patients with colorectal cancer, standard adjuvant
chemotherapy is combination therapy using 5-FU and
leucovorin. This approach has been confirmed by long-
term, randomized clinical trials. Since it has long been
known that histologically identical tumors may often differ
in their responses to treatment, there have been many
attempts to design in vitro assays that would be predictive
of in vivo response to chemotherapy. The advantages of a
successful assay would clearly improve clinical response
and reduce side effects, toxicity, and cost.
Various chemosensitivity tests have been developed and
studied for the past 20 years, however, they have not yet
been adopted on a widespread clinical basis due to a
variety of problems: insufficient in vitro-in vivo correlation,
long turnaround time (subrenal capsule assay and human
tumor clonogenic assay),5,6 low success rate of primary
culture, the need for a large amount of specimen assay
(methylthiazoletetrazolium (MTT), and histoculture drug
response assay (HDRA).7-9 ATP assay measures light
production as cellular ATP reacts with the luciferin-luci-
ferase complex. The quantification of the light produced
directly corresponds to the number of viable cells.10 The
success rate of ATP assay was not significantly different
from those of other in vitro studies, such as the MTT assay
or the HDRA, although the ATP assay has a higher overall
sensitivity and some technical advantages.8,10-15,24
Contrary to the differential staining cytotoxicity (DiSC)
assay, which is dependent on the morphologic differences
between tumor and normal cells, the measurement of the
amount of ATP or enzyme activity (MTT and HDRA) may
be affected by contaminated normal cells within the tumor
tissue.8,25,26 Kodera, et al.27 recently reported that no signi-
ficant correlation was observed between the results of an in
vitro chemosensitivity test and the survival of patients
using 3-dimensional gastric cancer tissue culture systems.
However, Iwahashi, et al.28 used another gastric chemosen-
sitivity test to show that overall survival in the test-guided
chemotherapy group was significantly better than those in
standard and non-chemotherapy groups. One reason for
these contradictory results may be that the Iwahashi’s
group used selective cancer cells, which are different from
the 3-dimensional tissue culture systems of the Kodera’s
group, strongly supporting the notion that the effective
elimination and inhibition of the proliferation of normal
cells are essential for valid conclusion in the chemosensiti-
vity assay. ATP-CRA, a newly-developed ATP assay, was
demonstrated in patients with lung cancer that normal cells
were effectively eliminated from the cancer tissue using
Ficoll gradient centrifugation.16
The success rates of the ATP assay using tissues of
various kinds of cancers (except colorectal cancer) ranged
from 85 to 91%.12-16,29-31 In general, colorectal tissues are not
easy to culture, because they are fibrous and do not disso-
DISCUSSION
Table 3. Heterogeneity of Chemosensitivity Index (CSI)*
5F OX IR ET GE PA
Tested no. 92 92 93 85 92 86
Frequency of 1st rank 10 10 23 19 1 20
Frequency of 2nd rank 11 17 20 14 1 20
Subtotal (%) 21 (22.8) 27 (29.3) 43 (46.2) 33 (38.8) 2 (2.2) 40 (46.5)
5F, 5-FU; OX, oxaliplatin; IR, irinotecan; ET, etoposide; GE, gemcitabine; PA, paclitaxel; TDC, test drug concentration.
*CSI  = 300 - sum (% CDR at 500, 100, and 20% TDC).
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Fig. 1. Mean value of CSI according to the histology (n = 73). Irinotecan had the
greatest responsiveness in patients with well differenatiated (WD, n = 7) and
moderately differentiated carcinoma (MD, n = 54), while paclitaxel had the
greatest responsiveness in those with poorly differentiated and mucinous
carcinoma (PD/MU, n = 12). However, there was no statistically significant
correlation between responsiveness and histology (p = 0.144).  CSI, Chemosen-
sitivity Index.
ciate in the enzymatic solution well. Our study using
colorectal cancer tissues showed that the success rate was
85.5%, which was a level similar to the previous reports
using non-colorectal cancers tissues.13-15 The mean CV of
our test was 9.2%, which was superior to the values
obtained by other studies (10.5-13.0%).16,29-32 In the present
study, the results of ATP-CRA were reported to physicians
within 7 days of specimen collection, therefore, the selection
and administration of anticancer drugs could be possible
without any delay.
Whitehouse, et al.17 showed that one of the main technical
difficulties in cell culture is microbial contamination in
ATP assay. In this study, we used a culturing system
containing different types of antibiotics at concentrations
that would not affect the results from the chemosensitivity
test. However, microbial contamination was the major
cause of failure in most cases (18/20, 90%). Additional
treatments with other antibiotics in future study are needed
to minimize experimental failure due to microbial conta-
mination.
There are several methods to obtain cancer tissues for
ATP assay, which include surgical resection, endoscopic
biopsy, and aspiration of peritoneal or pleural fluid from
metastatic lesions.16,17 In our study, we were able to obtain
sufficient amounts of tumor tissues from surgical resection
in all cases tested. Tumor tissue specimens were taken at
least 0.5 cm3 in size in the operating room, which was
sufficient quantity for successful assay because an average
of 32,196 cancer cells among 1 mg of tissue were isolated.
In the present study, we decided to exclude patients who
had undergone preoperative radiotherapy because irradia-
tion of colorectal tissues, with its fibrous nature, makes it
more difficult to isolate cancer cells.
We tested some experimental chemotherapeutic agents
that are not currently used in the treatment of patients with
colorectal cancer (e.g., etoposide, gemcitabine, and pacli-
taxel), but have been investigated in several preclinical and
research reports.17,22,23 Nakahara et al.22 used the collagen
gel droplet embedded culture sensitivity test and reported
that gemcitabine showed the highest efficacy among the
12 anticancer drugs tested in patients with colorectal
adenocarcinoma, suggesting that it might be a promising
drug for the treatment of human colorectal cancer. Taxanes
failed to demonstrate significant clinical benefit in phase II
trials in colorectal cancer, but further trials of taxanes may
possibly be indicated in patients with chromosomal
instability negative colorectal cancer.23 In this study, gem-
citabine produced very little growth inhibition in the
samples tested. Paclitaxel showed excellent activity in
samples with poorly differentiated and mucinous colo-
rectal cancer. These in vitro results appear contradictory to
previous reports,22,23 nevertheless, they suggest the possi-
bility of correlation of in vitro ATP-CRA results with
clinical response, possibly initiating randomized controlled
trials of ATP-CRA directed chemotherapy.
In our study, TDC of 6 anticancer drugs tested were the
plasma peak concentrations determined by training set
experiments, which exhibited a scattered distribution of
cell death from each specimen.20,21 That is, TDC was
defined as the drug concentration at which tumors show
the most heterogeneous inhibition rate. Based on these
results, we established new algorithms of test interpretation
and in vitro concentration of drug tested. Our newly
developed ATP-CRA method was described and validated
in preclinical and clinical studies.16,18,19,33 We previously
reported the clinical feasibility of our ATP-CRA in a study
on a limited volume of colorectal tumors.18,19 Moon, et al.33
showed that ATP-CRA and clinical outcomes correlated
well after assay-guided platinum-based 2-drug chemo-
therapy for unresectable lung cancer. Our results showed
considerable heterogeneous responsiveness between the
tumors tested to chemotherapeutic agents at a standard
concentration. Generally, the greater the drug effectiveness,
the higher the value of CDR and the lower the value of
CSI. The median values of CDR were relatively higher with
clinically active drugs (e.g., irinotecan, 5-FU, and oxali-
platin) than clinically non-active drugs (e.g., paclitaxel,
gemcitabine, and etoposide). Irinotecan had the highest
median value and the 2nd widest range of CDR. That is,
the conventional 5-FU treatment did not produce better
overall growth inhibition compared to that of irinotecan. It
is highly possible that a combination of 5-FU and irino-
tecan or oxaliplatin would show better activity in any
samples tested. Modern combination chemotherapy with
irinotecan, 5-fluorouracil, and leucovorin or oxaliplatin has
demonstrated superior response rates (31-56%) compared
with 5% for fluorouracil alone.34,35 This approach is una-
vailable in our current study, but mandatory for further
clinical application. Konecny, et al.15 reported that CSI was
superior to other parameters, possibly because this index
takes the in vitro tumor growth inhibition of all tested dose
levels into account, giving more complete information on
drug sensitivity at lower and higher dosages. However, it
has not yet been clearly determined which parameter (e.g.,
CDR vs. CSI) has more accurate information on drug
sensitivity using ATP-CRA. Hence, further studies are
warranted to identify more sensitive and accurate para-
meter of ATP-CRA.
We also tested whether histological type was correlated
with the effectiveness of all anticancer drugs tested. In
samples with moderately differentiated carcinoma appear-
ing the most common histology, irinotecan showed greater
responsiveness, followed by paclitaxel and etoposide. In
samples with well differentiated carcinoma, the most
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effective drug was irinotecan, and paclitaxel was the most
effective drug in those with poorly differentiated and
mucinous carcinoma. Although we found no statistically
significant association between responsiveness and histo-
logy (p = 0.144), there is a strong possibility that colorectal
cancers are heterogeneous in their sensitivity to chemo-
therapeutic agents, depending on the histological type of
carcinoma. Moreover, this in vitro result may enable sur-
geons to broaden the spectrum of which chemotherapeutic
agents are used.
Only randomized trials can demonstrate the superiority
of one chemotherapy regimen over another. The ASCO
Working Group on Chemotherapy Sensitivity and Resis-
tance Assays29,30 showed that the use of chemosensitivity
assays to select chemotherapeutic agents for individual
patients is not recommended outside the clinical trial
setting. Instead, however, oncologists should recommend
chemotherapy treatment on the basis of published clinical
trial reports. Since our preliminary study was to primarily
define the feasibility of ATP-CRA as a chemosensitivity
test in patients with colorectal cancer, a further confir-
matory study has to be performed. These include the
results of combination chemotherapy, ATP-CRA between
initial and recurrent colorectal cancers, ATP-CRA in rectal
cancer patients with neoadjuvant therapy, and comparison
of ATP-CRA-guided chemotherapy to empirical chemo-
therapy for advanced colorectal cancer. To define the
clinical benefit of assay-guided chemotherapy which is
based on the above results, a clinical trial targeting patients
with advanced colorectal cancer is underway at our insti-
tution. Our results and similar results published in other
studies should set the stage for a randomized, prospective
trial in the near future.
In conclusion, this preliminary study revealed that ATP-
CRA produced varying results that were dependent on
individual patients and could be a practical chemosensitivity
test in patients with colorectal cancer. However, the clinical
use of anticancer drugs with a chemosensitivity test should
be performed only in a limited scope because of the lack of
prospective randomized studies. Therefore, further long-
term follow-up studies with a larger group of patients are
warranted to evaluate the results of ATP-CRA.
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